Core Viewpoint - Modern Chinese Medicine Group (01643) expects to achieve a profit attributable to equity holders of no less than RMB 2 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 6.9 million for the six months ending June 30, 2024 [1] Company Performance - The board believes the turnaround from loss to profit is primarily due to a significant reduction in losses from the disposal of properties, plants, and equipment [1] - For the six months ending June 30, 2024, the company incurred substantial losses from the disposal of properties, plants, and equipment due to the demolition of the formulation workshop [1] Revenue Outlook - Despite the expected profit, the company's revenue is projected to decrease by 15% to 20% compared to the six months ending June 30, 2024 [1] - The board attributes the revenue decline to intense industry competition [1]
现代中药集团(01643)发盈喜，预期中期股东应占溢利不少于 200万元 同比扭亏为盈